Most of the currently used cancer chemotherapies are based on compounds that inhibit general cellular mechanisms, such as DNA replication or tubulin function, and lack specificity in relation to features of the cancer cell. Recent advances in genomic studies have increased our knowledge of tumor cell biology, and a panoply of new targets have been postulated. This has provided an opportunity to develop and validate drugs that specifically target cancer cells through their unique genetic characteristics. Identification of MUC16/CA125 both as a marker and a driver of transformation led us to design a target-based high-content screen to identify and classify compounds that exhibit differential effect on MUC16-expressing cells. We developed a coculture assay in 384-well plate containing isogenic ovarian cancer cells that are positive or negative for the MUC16 protein. High-throughput screening of our small-molecule pilot library led to the identification of compounds preferentially cytotoxic to MUC16-positive or -negative cells using a Preferential Score analysis. We compared screening results in both A2780 and SK-OV-3 ovarian cancer cells in single and co-culture settings. We also identified compounds that were cytotoxic for both types of ovarian cancer cells regardless of the MUC16 status.
INTRODUCTION
Treatments for human malignancies are evolving from classic cytotoxic chemotherapy agents to more sophisticated targeted therapy (1, 2) . Since uncontrolled proliferation has been a hallmark of malignant behavior, many of the cytotoxic compounds in current use have been directed toward DNA synthesis, damage, and repair processes. More recently, knowledge about molecular biology of cancer cells has afforded new opportunities to address other cancer-specific traits and decrease the host toxicity from cancer therapeutics. The Cancer Genome Atlas (TCGA) promises to provide a new catalog of cancer targets based on mutation, allelic loss, gene amplification, altered gene expression, and other cancer-specific changes to the DNA, RNA, and protein profile of the cancer cells (3) . However, the high-throughput technologies of the TCGA focus on nucleic acids will need to be complemented by biologic studies confirming the value of the target abnormalities identified. Since epithelial cancers can show dozens or hundreds of changes in genetic expression, there is an urgent need to validate targets nominated because of altered gene expression and select cancer-specific targets for therapeutic development.
Ovarian cancer is the most common cause of death from gynecologic malignancy in the developed world (4, 5) . The tethered mucin MUC16/CA125 is elevated in about 80% of ovarian cancers, but is not expressed significantly outside the female reproductive track (6, 7) . This selectivity has been utilized for both disease monitoring and therapeutic intervention (8, 9) . The regulation of MUC16 expression in cancer cells is not well understood (7) .
CA125 has been shown to be an independent adverse prognostic factor in clinical studies.
In results from the TCGA, MUC16 amplification or mutations are present in more than 10% of all serous ovarian tumors, suggesting that either transcriptional or post transcriptional regulation changes must be common in ovarian cancer (10, 11) . Targeting MUC16/CA125 may be an effective strategy for ovarian cancer-specific therapy but thus far, no clinical approach to MUC16/CA125 targeting has been successful. We have also established that expression of even small portions of the MUC16 gene transforms 3T3 cells and confers an invasive, more aggressive phenotype (manuscript submitted). These characteristics imply that MUC16 confers novel biological properties to cancer cells that are both selective and functionally important.
By using isogenic cell lines of different backgrounds (e.g., A2780 and SK-OV-3), each differing only in the expression of physiologic levels of MUC16, we can readily isolate MUC16-specific effects for investigation of biology and therapy (6) . High-content screening offers several advantages because one can measure simultaneously different cell features and exclude compounds that have nonspecific, off-target effects on cellular viability, morphology, and behavior. The goal of this study was to introduce and implement a dual-fluorescence isogenic screening strategy to identify and classify small molecules that specifically target cells differing from the parental line by expression of a single protein (12) . In this pilot study, we establish the feasibility of an isogenic dual-fluorescence screening application for identification of MUC16-specific compounds for development in the treatment of ovarian cancer.
MATERIEALS AND METHODS
Cell lines: A2780 cells were obtained as a gift from Dr. Thomas Hamilton (Fox Chase Cancer Center) and cultured in RPMI-1640 with 10 mM HEPES, 10% fetal bovine serum (FBS, Hyclone,Logan, UT), 2mM L-glutamine and 0.2 U/ml insulin (Eli Lilly & Co, Indianapolis, IL), penicillin 100 U/ml, and streptomycin 100 μg/ml. The SK-OV-3, SK0V8, CAOV3 and OVCAR3 cells were obtained through the American Type Culture Collection (ATCC, Manassas, VA) and propagated according to those instructions. The T80 immortalized human ovarian epithelial cells were the generous of Dr. Robert Bast. MUC16 fragments were created using pBK-CMV-MUC16-B53 DNA as a template and introduced into EcoRV and NotI multiple cloning sites of the phrGFP II-C vector (Stratagene, LaJolla, CA) (6, 13) . These constructs, containing elements of MUC16 (MUC16   c678   -GFP and MUC16   c344 -GFP ), were transfected into CA125-negative ovarian cell lines A2780 and SK-OV-3, respectively. In the SKOV8 cells, an siRNA to CA125 was introduced in a pSilencer vector to reduce the MUC16 expression with a scrambled siRNA which had no effect (Awtrey C, personal communication). We also Cell growth in single or co-culture in 384-well plate: A2780-GFP and A2780-MUC16/mCherry cells were plated separately or simultaneously in 384-well plates at different final cell density: 250, 500, 1000, and 1500 cells per well. When A2780-GFP and A2780-MUC16/mCherry cells were co-cultured; a ratio of 1:1 was used. Plates were fixed and stained as described above at 48h, 72h, and 96h after plating and analyzed on the IN Cell 1000. Twenty- four hours before each time point, 5μL of Alamar Blue (AbD Serotec, Oxford, UK) were added and conversion of resazurin was assessed using the LEADSeeker (GE Healthcare, Piscataway, NJ). The data from growth were curve experiments analyzed on the log scale. Effect of time was estimated using linear regression. Image analysis: Images were analyzed using the developer Toolbox Software (GE Healthcare, Piscataway, NJ) where a custom-built algorithm was designed to segment GFP and mCherry cells based on the Hoechst segmentation. The count of GFP, mCherry, and Hoechst objects per well was used as the measurement. Batch analysis was performed to process all plates.
Caspase-3 activity assay: A Caspase-3 Activity Assay kit was purchased from Roche Diagnostics GmbH, Germany and used according to manufacturer's instructions. Assays were performed in quadruplicate, and means were evaluated using Student's t test between MUC16-negative and MUC16-positive cells. The assays were repeated at least 3 separate times.
RESULTS

Co-culture of fluorescence-labeled cells
To identify small molecules that target preferentially the MUC16 protein, we co-cultured in the same well two isogenic cell lines that differ only by expression of the MUC16 protein. The protein encoded by MUC16 is a large glycoprotein that consists of a small cytoplasmic Cterminal, a potential external cleavage site and a tandem repeat domain that covers most of the external part of the protein (Fig. 1a) . We expressed the carboxy terminus of the molecule, using the last 344-678 amino acids that include one or more of the tandem repeat sequences recognized as the CA125 antigen. Using both parental A2780 and SK-OV-3 human ovarian cancer cells, we engineered A2780-GFP and SK-OV-3-GFP cells that expressed GFP fluorophore alone.
A2780-mCherry and SK-OV-3-mCherry cell lines were engineered that expressed the combination of mCherry fluorophore and the carboxy terminal region of the MUC16 protein. Markers expression was confirmed by FACS analysis. Expression of the transgene was not completely uniform. About 80% of A2780-GFP cells were found GFP-positive, whereas about 71% of A2780-mCherry were mCherry-positive (Fig. 1b) . This difference in GFP and mCherry proportions could be explained by the different imaging settings used for the FACS and microscopy techniques. Low GFP and mCherry signals captured by the microscope were excluded to avoid any measurement of background noise in the analysis.
We had previously established that the growth characteristics of the cell lines in vitro were identical. For the high-content screen, we assessed the cell growth for the A2780-GFP and mCherry-labeled cell lines cultured separately in 384-well plates from 48-96h of incubation ( Similar results were obtained when measuring the cellular proliferation by metabolic activity measurement using the Alamar Blue assay (Suppl . Fig. 1a) . Co-culture of A2780-GFP and A2780-mCherry cells was also examined. The cells were seeded into 384-well plate at 1:1 ratio and cell growth was determined as described above. The growth curves from the same initial cell-seeding density (500-1500 cells per well) were generated and compared with those from the single-cell-line cultures. A2780-GFP or A2780-mCherry grown separately or in co-culture grew at the same rate ( Fig. 1d-f; Suppl. Fig. 1b) 
72h growth period were selected as final test conditions. Similar studies were done for the SK-OV-3 isogenic pair studies, and 1500 cells per well was chosen.
Target-based high-content screen
The dual-color fluorescence cellular assay was developed to perform in a miniaturized 384-well microplate format. In the initial study, the paired A2780 cell-line constructs were seeded into 384-well microplates containing 10μM of test compounds in 1% DMSO (v/v) at a final density of 1500 cells/well. For controls, 1% DMSO (v/v) was used as a High control and 10μM of Killer Mix in 1% DMSO (v/v) was used as a Low control. The cells were incubated with compounds for 72 hours, followed by fixation in 4% paraformaldehyde and staining with Hoechst to identify nuclei. Finally, the plates were imaged on the In Cell Analyzer 1000 (GE Healthcare, Piscataway, NJ), and cytotoxicity was assessed by custom analysis module using Developer configured for fluorescence object count. We performed a control run to assess the inter-and intra-plate variability using High control (1% DMSO) and Low Control (10μM Killer Mix) plated in 3 different plates each (Suppl . Fig. 2a&b) . The control plates with 1% DMSO and 10μM Killer Mix gave a Z' of 0.50 and 0.54 for GFP and mCherry, which indicated that the assay was both robust and amenable to high-throughput screening.
Using the pilot compound library (15) and the screening conditions described, we performed three separate assessments, one with the A2780-GFP control cells, one with the A2780-mCherry-MUC16+ cells, and a third with co-culture (Fig. 2) . Each of these analyses was performed in duplicate (noted as set 1 and set2) and the results are presented in Fig. 3 . In panel 3a, the correspondence of the two GFP replicates is presented as the size and the color of the dot for each compound. The consistency of the replicate analyses is illustrated through the (Fig. 3b) or SK-OV-3 mCherry (Fig. 3d) screen is represented by the size and blue intensity of the individual dots, each representing a single compound. The position on the X-Y axis represents the homology between the two dual culture replicates, while the distance from the origin represents the compound activity against the specified cell line. A two dimensional analysis of the replication data, presented as nuclear counts, is presented in Supplemental Figure 3 .
The correspondence between the SK-OV-3 and A2780 cell isogenic screens is shown in The most positive results for the A2780 and SK-OV-3 analyses are shown in Table 1a .
We initially identified thirteen relatively selective MUC16 candidate compounds, as shown in Table 1a , including carboplatin, quinacrine, andrographolide, oxyphenbutazone, acriflavinium, and rutilantinone, which appeared to be selectively more toxic for the MUC16-expressing A2780-mCherry cells, based on the selection criteria of individual PS >3 for both the individual analyses and the dual-fluorescence study. This gave an initial screening value of 0.416% tested compounds. The A2780 dual screening co-culture system was highly representative of the individual results, both in selectivity and magnitude of effect (Table 1a , columns 3 -8). This consistency will decrease the complexity of the screening in the future and provide a cheaper, more efficient and specific strategy for high-content screening of the MUC16 target lesion.
The confirmatory screens for the same compounds with a second dual-fluorescence isogenic ovarian cancer cell pair (SK-OV-3) are shown in Table 1a , from columns 9-14. As can be seen, only one compound, quinacrine, had a confirmed specificity for MUC16+ cells over the parental MUC16(-) cell line. The structures are shown in Table 1b . Based on the dual selection with the two independent cell-based assays, only quinacrine was consistently more toxic to MUC16-expressing cells in both the A2780 and the SK-OV-3 dual-fluorescence screens.
Additional comparisons for these 4 compounds were done for 2 additional isogenic cell line pairs in Table 1c , confirm that, for the most part, the expression of MUC16 conferred a modest sensitivity to each agent compared to matched the MUC16 negative isogenic cell line.
In order to confirm these findings in a different functional assay, induction of apoptosis was used to validate the screening results in both A2780 and SKOV3 matched cell lines. We examined the effect of quinacrine and three other A2780 screen-nominated compounds (ellipticine, acriflavinium hydrochloride, and rutilantinone) (Fig. 5 ) that met the selection criteria for MUC16 targeting in the A2780 pair but not in the SK-OV-3 assay. No compound was found to be MUC16 selective in SK-OV-3 cell screen that was not also identified as selective in the A2780 cell pair. Table 1a ) were tested for the induction of caspase-3 activity (a marker of apoptosis) in both of the test cell-line pairs (Fig. 5b&c) . Only quinacrine statistically increased caspase-3 activation in the A2780-MUC16-mCherry-positive cells compared with the A2780-phrGFP cells (p<0.0001) (Fig. 5a&b) . In SKOV3-MUC16-mCherry transfectants, caspase-3 activation was significantly elevated compared with the vector control for quinacrine but not for rutilantinone, ellipticine, and acriflavinium. Thus, in both cell- screening system allowed the early selection of candidate compounds that were MUC16-specific before the slower, labor-intensive confirmatory screening was performed by hand.
Four compounds (highlighted in yellow in
DISCUSSION
As The Cancer Genome Atlas is completed for specific tumors, the biology of various target genetic alterations will need to be confirmed, and the opportunities for targeting specific genetic alterations will increase very rapidly. Efficient strategies for lead compound generation will be needed to accelerate development and credentialing of individual cancer-specific targets. In this work, we describe the implementation of strategy for high-throughput screening of a single genetic alteration, using a syngeneic, dual-fluorescence strategy. For some genes, it is possible to quickly select candidate compounds for drug development. In this co-culture method, the cost of sequential screening can be avoided, and variation between the screening steps is reduced.
Within each well, the variations in dispensing, handling, location/edge effects have been excluded and the procedure is highly economical, based on the small volume of each test well.
The co-culture strategy is clearly dependent on a similar growth curve between the two isogenic pairs.
In this study, we demonstrate that use of two different cell pairs, each isogeneic except for MUC16 expression, provided a highly selective screen and allowed a high probability of true "hits" that are independent of the background cell biology of the different tumor cell lines. This redundancy in different cellular backgrounds was able to rapidly eliminate inconsistent effects that depend more on cellular context than on the specific genetic alteration under study. By stringently defining hits as positive wells in two independent systems, the high-throughput 
approach described herein led to a very low rate of unconfirmed candidacy, and in a full screening enterprise, would facilitate selection of candidates for further drug development.
The co-culture system was also validated in the comparison with the individual culture results. The co-culture results were highly consistent with the individual culture data and were relatively consistent across the two screening systems. In this study, only quinacrine was actually selected as a positive, MUC16 selective "hit" after the confirmatory screen. A simpler, co-culture analysis of the two test systems would have called the same single compound positive, and no false positives were identified in the 3,119 compounds that completed the entire double selection testing. The independent confirmation by caspase-3 activation represented a separate mechanism that did not depend on growth inhibition alone and gives further confirmation regarding the validity and specificity of the high-content-screening results. While our selection rule is highly stringent, it greatly increases the specificity of the MUC16 targeting and has the advantage of a "hit rate" below 0.1% which will hopefully yield a tractable number of hits for secondary screening when several hundred thousand compounds are tested.
The applications of this isogenic, dual-fluorescence strategy are potentially broad.
Screening of a much larger library is likely to be successful in identification of MUC16+ hits.
Our pilot data suggest that this strategy may yield fewer than 1 hit/thousand candidates from a larger library, quickly reducing the number of potential therapeutic agents into a manageable number for more extensive confirmation. Alternatively, a third isogenic pair could be used to further validate the selective nature of the selected compounds, if a large, unmanageable number were identified from the 2 cell-line panels. The technique could also be readily adapted to 
would readily facilitate the selection of targets that could be subsequently confirmed by additional siRNA candidates.
Certain limitations are also notable. The studies would be much more complex if the MUC16+/-cell lines were not identical in their growth characteristics over the days of evaluation. Any paracrine or endocrine interactions between the cancer and the host would be much more difficult to model in this system, and the advantages of high-content screening would be lost. Finally the selective expression of MUC16 in mullerian tissue is an important advantage (6) . If the expression of the target is not essentially confined to tumor tissue, the selectivity in vitro might be insufficient to nominate candidates for additional testing. Nonetheless, this is the first practical implementation of an isogenic, dual-fluorescence high-content screen for cancer drug development. The screen is now being applied to a library of over 350,000 compounds for additional testing. 
